Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A9 | P06702 | 4/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235469 | 0.84 | S100A9 (0.60) | S100A9PTGES2SLC22A12KDM4E | |
| SCHEMBL16235088 | 0.81 | S100A9 (0.56) | S100A9ALPLPTGES2SLC6A4PDE5A | |
| SCHEMBL16235384 | 0.77 | S100A9 (0.67) | S100A9KDM4E | |
| SCHEMBL16235290 | 0.71 | S100A9 (0.45) | S100A9ALPLPTGES2SLC22A12SLC6A4 | |
| SCHEMBL16235308 | 0.71 | S100A9 (0.59) | S100A9PTGES2SLC22A12SLC6A4KDM4E | |
| SCHEMBL16235285 | 0.70 | CCR4 (0.61) | — | |
| SCHEMBL2061316 | 0.69 | LRRK2 (0.70) | LRRK2 | |
| SCHEMBL2061366 | 0.69 | LRRK2 (0.57) | LRRK2KDM4EPDE5A | |
| SCHEMBL16235642 | 0.69 | S100A9 (0.48) | S100A9LRRK2KDM4ESCN9A | |
| SCHEMBL16235448 | 0.69 | HCRTR2 (0.41) | LRRK2ALPLSLC22A12KDM4ESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-11-13 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2925743-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | S100A9, S100B, S100A10 | S100A9 1/4885LRRK2 717/4885ALPL 2152/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | S100A9 1/4885LRRK2 717/4885ALPL 2152/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | S100A9 1/4885LRRK2 415/4885ALPL 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.